NCT04591275已完成3 期
Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared with Prolia® in Chinese Postmenopausal Women with Osteoporosis At High Risk of Fracture.
Shanghai Biomabs Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 278 人开始时间: 2021年3月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 278
- 试验地点
- 1
- 主要终点
- BMD percentage change from baseline at lumbar spine(L1~L4)
研究概览
简要总结
evaluate the differences in effectiveness and safety between CMAB807( potential biosimilar) and Prolia(original product)
详细描述
this is a randomized, double-blinded, parallel, active-controlled clinical phase III study. the primary objective is to evaluate the efficacy and safety of CMAB807 treatment compared with Prolia in Chinese postmenopausal women with osteoporosis at high risk of fracture.
Subjects should sequentially enrolled according to the protocol in one of two arms. Subjects who entered in test arm would receive 60mg of CMAB807 subcutaneously every 6 months for one year, while those who entered in control arm should receive 60mg of Prolia subcutaneously every 6 months for one year. Meanwhile, every subject should taking 600mg calcium and 400IU vitamin D daily from successfully screening to the end of study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Fully informed, understood, voluntary participate, and the patient himself or guardian agree to sign the written informed consent and patient be able to comply with the protocol;
- •Aged from 50 years to 85 years, inclusive;
- •Spontaneous amenorrhea time ≥ 2 years, or bilateral oophorectomy≥ 2 years. If the status of bilateral ovariectomies is unknown, the menopause status should be confirmed by follicle stimulating hormone(FSH) level≥ 40IU/L;
- •Based on the results of dual energy X-ray absorptiometry, BMD of lumbar spine(L1~L4), femoral neck or total hip: -4.0<T-Score≤-2.5；
- •There must be at least one of the following risk factors:
- •History of osteoporotic fracture;
- •Father's and mother's hip fracture history, or both parents';
- •Low body mass index(≤19kg/m^2);
- •Patient's age was equal or greater than 70 years old;
- •Current smoker;
- •CTX1 was one standard deviation higher than that of healthy premenopausal women within screening period(ie, CTX1>0.43ng/mL);
- •Ability to act independently.
排除标准
- •Suffering from the following diseases known to affect calcium or bone metabolism:
- •Various metabolic bone diseases, such as osteogenesis imperfecta and osteomalacia;
- •Paget's osteopathy;
- •Cushing's syndrome;
- •Hyperprolactinemia;
- •Hypopituitarism;
- •Acromegaly;
- •History of hyperparathyroidism or hypoparathyroidism;
- •History of hyperthyroidism or hypothyroidism(hypothyroidism patients can be included: only receiving stable thyroid hormone replacement therapy, if the thyroid stimulating hormone(TSH) level is normal, or 5.5μIU/mL<TSH≤10.0μIU/mL, and free thyroxine(FT4) is in normal range can be included);
- •Malabsorption syndrome or various gastrointestinal diseases associated with malabsorption, such as Crohn's disease and chronic pancreatitis;
- •Abnormal level of blood calcium: the current diagnosis of hypocalcemia or hypercalcemia or albumin corrected serum calcium levels are not within the laboratory normal range(calcium supplements should not be used for at least 8 hours prior to serum calcium testing);
- •Vitamin D deficiency: 25 hydroxyvitamin D concentration<20ng/mL. Allowed to retest after oral vitamin D2 soft capsules in the screening period. If the concentration of 25 hydroxyvitamin D is more than or equal to 20ng/mL， it can be selected;
- •Other diseases such as rheumatoid arthritis, gout, multiple myeloma, etc;
- •Medical history of two or more vertebrae fractures;
- •Malignant tumor(excluding skin basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ or breast ductal carcinoma in situ) in recent 5 years;
- •Severe renal function damage(creatinine clearance rate<30mL/min), or dialysis, urinary calculi or chronic cystitis;
- •Suffering from the following liver or biliary diseases:
- •Liver cirrhosis;
- •Biliary abnormalities(except for Gilbert syndrome or asymptomatic gallstones);
- •Positive hepatitis C virus antibody(HCV-Ab) and the titer of HCV-RNA exceeded the upper limit of norma;
- •Positive hepatitis B suface antigen(HBsAg) and peripheral blood HBV-DNA titer ≥1000 capies[CPS]/mL or 200IU/mL;
- •Unstable liver disease: defined as liver ascites, hepatic encephalopathy, coagulopathy, hypoalbuminemia, varicosis in esophagus or stomach fundus or persistent hepatic jaundice;
- •Liver transaminase: aspartate aminotransferase≥2.0×upper limit of norma value(ULN), alanine aminotransferase≥2.0ULN, alkaline phosphatase≥1.5ULN or total bilirubin≥1.5ULN;
- •Suffering from the following oral diseases:
- •Osteomyelitis or osteonecrosis of the jaw, previously or currently;
- •Actue dental or mandibular disease requiring stomatological surgery;
- •Planned invasive dental surgery during the trial period;
- •Dental or stomatological surgery have not healed;
- •Conditions which can influence bone mineral density determination by dual energy X-ray absorptiometry:
- •Less than two lumbar vertebrae can be measured;
- •Height, weight or waistline may hinder accurate measurement;
- •Other conditions that may affect bone density testing
- •Received anti-osteoporosis drugs or those drugs may affect bone metabolism:
- •Use of injectable bisphosphonates, fluoride or strontium within 2 years before screening;
- •Use of oral bisphosphonates: more than 2 years, or more than 3 months but less than 2 years and discontinued from last dosage less than 1 year, simultaneously;
- •Usage of any drugs which may affect bone metabolism within 6 weeks before screening: parathyroid hormone or parathyroid hormone analogue(such as teriparatide); assimilative hormone or testosterone; glucocorticoid(equivalent to prednisone>5mg/day for more than 10 days); systemic hormone replacement therapy; selective estrogen receptor regulator(such as reloxifene); tibolone; calcitonin; active vitamin D and ite analogues, other bone active drugs include anticonvulsant drugs(except benzodiazepines) and he[arin; long-term systemic use of ketoconazole, androgen, adrenocorticotropic hormone, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin releasing hormone agonist;
- •Patients who have received RANKL inhibitors previously;
- •Positive HIV antibody;
- •Known alcoholism or drug abuse(during 12 months before screening), because alcohol or drug abuse may interfere with subject's understanding or finish of trial;
- •Known allergy to test drug, reference drug or basic drug and its excipients;
- •Participate in interventionary clinical study(drug or device) within one month before screening;
- •Other serious, acute or chronic diseases, mental disorders or laboratory abnormalities, which are judged by investigator to be unsuitable to participate this study.
研究组 & 干预措施
CMAB807
Experimental
60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
干预措施: CMAB807 Injection (Drug)
Prolia®
Active Comparator
60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
干预措施: Prolia® (Drug)
结局指标
主要结局
BMD percentage change from baseline at lumbar spine(L1~L4)
时间窗: baseline, at 12 months
Percentage change from baseline at lumbar spine(L1\~L4) by dual-energy X-ray absorptiometry to month 12 of treatment and compare between two arms. Percentage change of lumbar spine BMD from baseline to at month 12 of treatment=(BMD at month 12 of treatment - BMD at baseline)/BMD at baseline\*100%
次要结局
- BMD percentage change from baseline at total hip, trochanter and femoral neck(baseline, at month 6, at month 12)
- BMD percentage change from baseline at lumbar spine(L1~L4)(baseline, at 6 months)
- Serum CTX1 and P1NP concentration percentage change from baseline(baseline, at month 1, at month 3, at month 6, at month 9,and at month 12)
- Proporation of new osteoporotic fractures(vertebrae, total hip and non-vertebrae) occurring within the study period(baseline, at month 12)
- Adeverse events and serious adverse events(baseline ,at 12 months)
- Population pharmacokinetics analysis(baseline, at 12 months)
- Immunogenicity(baseline, at 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy VolunteersHealthy VolunteersNCT05808673Taizhou Mabtech Pharmaceutical Co.,Ltd
终止
2 期
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the WombEndometriosisNCT04614246Bayer215
已完成
不适用
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and NeutropeniaNeutropeniaNCT00008840National Institute of Allergy and Infectious Diseases (NIAID)866
已完成
1 期
Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy VolunteersHealthy VolunteersNCT06361355Taizhou Mabtech Pharmaceutical Co.,Ltd128
已完成
3 期
A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)Postoperative PainNCT00092378Merck Sharp & Dohme LLC251